Recent advances in cardiovascular medicine: The tenth Iranian congress on cardiovascular update

Archives of Iranian Medicine

Volumn 12, Issue 2, 2009, Pages 213-216

  Gasparyan, Armen Yuri ^a,b   Mohammad Hasani, Mohammad Reza ^c   Hassoun, Heitham ^d,e   Darban, Hamid ^f  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; PACLITAXEL; RAPAMYCIN;

ANGIOCARDIOGRAPHY; ATHEROGENESIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BARE METAL STENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DRUG ELUTING STENT; DRUG SAFETY; FUNCTIONAL STATUS; GENETIC PREDISPOSITION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IRAN; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; METABOLIC SYNDROME X; MULTIDETECTOR COMPUTED TOMOGRAPHY; SECONDARY PREVENTION; SURGICAL TECHNIQUE; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULITIS; PATHOPHYSIOLOGY;

CARDIOVASCULAR DISEASES; HUMANS; IRAN; SOCIETIES, MEDICAL;

EID: 67649803258     PISSN: 10292977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008; 51: 1829-1843.
2. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006; 367: 606-617.
3. Patel D, Moonis M. Clinical implications of aspirin resistance. Expert Rev Cardiovasc Ther. 2007; 5: 969-975.
4. Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K, Sanatkar M, Gasemi M, Mirkhani H, et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med. 2007; 10: 467-473.
5. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007; 315: 1278-1282.
6. Etemadi A, Malekzadeh R. Definition and etiology of metabolic syndrome. Arch Iran Med. 2008; 11: 1-2.
7. Kelishadi R. Childhood overweight, obesity, and the metabolic syndrome in developing countries. Epidemiol Rev. 2007; 29: 62-76.
8. Kelishadi R, Ardalan G, Gheiratmand R, Gouya MM, Razaghi EM, Delavari A, et al. Association of physical activity and dietary behaviors in relation to the body mass index in a national sample of Iranian children and adolescents: CASPIAN Study. Bull World Health Organ. 2007; 85: 19-26.
9. Antar KA, Keiser HD, Peeva E. Relapsing arterial aneurysms in juvenile Behçet's disease. Clin Rheumatol. 2005; 24: 72-75.
10. Nichols L, Lagana S, Parwani A. Coronary artery aneurysm: a review and hypothesis regarding etiology. Arch Pathol Lab Med. 2008; 132: 823-828.
11. Kume T, Okura H, Kawamoto T, Akasaka T, Toyota E, Watanabe N, et al. Relationship between coronary remodeling and plaque characterization in patients without clinical evidence of coronary artery disease. Atherosclerosis. 2008; 197: 799-805.
12. Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, et al. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol. 2007; 50: 1123-1131.